Medical Peptides Group: Structural Diversity Driving Therapeutic Innovation
Title: Medical Peptides Group: Structural Diversity Driving Therapeutic Innovation Abstract: The Medical Peptides Group leverages structural diversity to propel therapeutic innovation across oncology, metabolic, and anti-aging applications. Current market trends show a 12.5% CAGR (2024-2030), driven by GLP-1 agonists and antimicrobial peptides. Key brands (e.g., Bachem, PolyPeptide) compete on purity (>98% HPLC) and scalability. Advantages include high specificity and low toxicity; limitations involve poor oral bioavailability and high synthesis costs. Product parameters vary by chain length (2-50 amino acids) and modification (PEGylation, acetylation). Regulatory compliance (GMP, FDA DMF) and cold-chain logistics (2-8°C) are critical for efficacy. Selection criteria prioritize stability, solubility, and target affinity. The industry faces supply chain bottlenecks but shows robust growth, with peptide drugs projected to exceed $50 billion by 2030.